10-QPeriod: Q1 FY2020

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 2020

Filed May 7, 2020For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb (BMY) reported its first quarter 2020 results, a period marked by the significant impact of the acquisition of Celgene, which closed in November 2019. The company demonstrated strong revenue growth, primarily driven by the acquired Celgene portfolio, with key products like Revlimid, Pomalyst, and Abraxane showing robust performance. Despite increased operating expenses due to the integration of Celgene, the company managed to deliver solid earnings, reflecting successful synergy realization and underlying business strength. Investors should note the positive top-line momentum and the strategic integration progress as key indicators of future performance, while also keeping an eye on ongoing research and development pipelines and potential challenges in the evolving pharmaceutical landscape. Looking ahead, BMY is focused on leveraging the expanded portfolio and R&D capabilities to drive sustainable growth. The company's ability to effectively integrate Celgene and realize projected synergies will be critical. Management's commentary suggests confidence in the company's strategic direction and its capacity to navigate market dynamics. Investors will likely be assessing the company's progress in drug development, commercial execution across its expanded product offerings, and its commitment to returning value to shareholders through dividends and potential share repurchases, all while managing the financial implications of the significant acquisition.

Financial Highlights

56 data points
Beta

Revenue

$10.78B

66.0% Gross Margin

Net Income

-$775.00M

-7.2% Net Margin

EPS (Diluted)

$-0.34

Total Assets

$129.28B

Cash & Equivalents

$15.82B

Free Cash Flow

$3.75B

Financial Statements
Beta
Revenue$10.78B
Cost of Revenue$3.66B
Gross Profit$7.12B
R&D Expenses$2.37B
SG&A Expenses$1.61B
Operating Expenses$11.09B
Interest Expense$362.00M
Net Income-$775.00M
EPS (Basic)$-0.34
EPS (Diluted)$-0.34
Shares Outstanding (Basic)2.26B
Shares Outstanding (Diluted)2.26B

Key Highlights

  • 1Strong revenue growth driven by the inclusion of the Celgene portfolio, particularly from key products like Revlimid, Pomalyst, and Abraxane.
  • 2Significant increase in operating expenses due to the integration of Celgene, impacting profitability compared to the prior year period without Celgene.
  • 3Effective management of cash flows from operations, demonstrating the underlying strength of the combined business post-acquisition.
  • 4Continued investment in research and development, highlighting the company's commitment to innovation and future growth drivers.
  • 5Detailed discussion on the financial condition and results of operations, providing transparency on the impact of the Celgene acquisition and ongoing business performance.
  • 6Disclosure of legal proceedings and risk factors, which is standard for public companies but important for investors to understand potential liabilities and market challenges.
  • 7Submission of matters to a vote of security holders, indicating corporate governance activities during the period.

Frequently Asked Questions

The primary driver of revenue growth was the inclusion of the Celgene portfolio, following the completion of the acquisition in November 2019. Key products from Celgene, such as Revlimid and Pomalyst, alongside Abraxane, demonstrated strong performance and significantly contributed to the top-line results.

The integration of Celgene has led to a significant increase in operating expenses, including costs related to the acquisition and integration process. While this impacts reported profitability compared to the prior year, management's focus is on realizing projected synergies and driving long-term value from the combined entity.

Management's discussion indicates confidence in the strategic direction and the expanded portfolio's potential to drive sustainable growth. Key areas of focus include continued R&D investment, successful commercial execution of the integrated product lines, and realizing integration synergies. Investors should monitor progress in these areas for insights into future performance.

The filing mentions 'Legal Proceedings' and 'Risk Factors' in Part II. While detailed information requires reviewing those specific sections, it's standard for pharmaceutical companies to face legal challenges and market-related risks. Investors should consult these sections of the 10-Q for specific disclosures on potential liabilities and operational risks.